Terug
33
Dagbereik
€ 0,01
€ 14,22
52-Weeksbereik
€ 0,01
€ 14,22
Volume
1.479
50D / 200D Gem.
€ 14,22
/
€ 14,22
Vorige Slotkoers
€ 14,22
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -5,6 | 0,4 |
| P/B | 1,3 | 2,9 |
| ROE % | -22,8 | 3,8 |
| Net Margin % | -7,3 | 3,9 |
| Rev Growth 5Y % | 9,5 | 10,0 |
| D/E | 5,1 | 0,2 |
Belangrijkste Punten
Revenue grew 9,48% annually over 5 years — modest growth
Earnings declined -130,41% over the past year
Debt/Equity of 5,14 — high leverage
Generating 328,61M in free cash flow
PEG of 0,05 suggests growth is underpriced
Capital efficient — spends only 2,55% of revenue on capex
Groei
Revenue Growth (5Y)
9,48%
Revenue (1Y)8,42%
Earnings (1Y)-130,41%
FCF Growth (3Y)14,42%
Kwaliteit
Return on Equity
-22,82%
ROIC-0,27%
Net Margin-7,31%
Op. Margin-0,68%
Veiligheid
Debt / Equity
5,14
Current Ratio0,72
Interest Coverage-0,10
Waardering
P/E Ratio
-5,57
P/B Ratio1,33
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,42% | Revenue Growth (3Y) | 9,73% |
| Earnings Growth (1Y) | -130,41% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 9,48% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 5,64B | Net Income (TTM) | -412,07M |
| ROE | -22,82% | ROA | -3,07% |
| Gross Margin | 80,01% | Operating Margin | -0,68% |
| Net Margin | -7,31% | Free Cash Flow (TTM) | 328,61M |
| ROIC | -0,27% | FCF Growth (3Y) | 14,42% |
| Safety | |||
| Debt / Equity | 5,14 | Current Ratio | 0,72 |
| Interest Coverage | -0,10 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -5,57 | P/B Ratio | 1,33 |
| P/S Ratio | 0,41 | PEG Ratio | 0,05 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 2,29B | Enterprise Value | 10,63B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 5,64B | 5,20B | 4,68B | 4,30B | 3,92B |
| Net Income | -412,07M | 1,35B | -4,03B | 65,19M | 160,05M |
| EPS (Diluted) | -2,62 | 652,97 | -3116,52 | 47,68 | 117,17 |
| Gross Profit | 4,51B | 655,93M | -91,39M | 277,71M | 459,68M |
| Operating Income | -38,20M | -918,73M | -664,29M | 364,61M | 426,42M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 13,41B | 13,91B | 14,49B | 17,07B | 16,97B |
| Total Liabilities | 11,69B | 12,02B | 16,00B | 14,74B | 13,48B |
| Shareholders' Equity | 1,72B | 1,89B | -1,50B | 2,32B | 3,50B |
| Total Debt | 8,86B | 9,16B | 13,38B | 12,13B | 10,53B |
| Cash & Equivalents | 518,72M | 644,95M | 856,42M | 952,37M | 888,84M |
| Current Assets | 1,88B | 2,37B | 1,91B | 2,42B | 1,86B |
| Current Liabilities | 2,62B | 3,12B | 9,96B | 3,54B | 2,63B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#339 of 616
Recente Activiteit
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026